alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit32.2**

 

CERTIFICATIONPURSUANT TO

18 U.S.C. SECTION1350,

AS ADOPTEDPURSUANT TO

SECTION 906 OF THESARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of 1stColonial Bancorp, Inc. (the “Company”) on Form 10-QSB for the period ended September30, 2004, as filed with the Securities and Exchange Commission on the datehereof (the “Report”), I, Robert C. Faix, Chief Financial Officer of theCompany, certify, pursuant to 18 U.S.C. 1350, as adopted to section 906 of theSarbanes-Oxley Act of 2002, that:

 

(1)           theReport fully complies with the requirements of section 15(d) of the SecuritiesExchange Act of 1934; and

 

(2)           theinformation contained in the Report fairly presents, in all material respects,the financial condition and result of operations of the Company.

 

 
| /s/ Robert C. Faix      |   |
|-------------------------|--------|
| Robert C. Faix          |
| Chief Financial Officer |
| November 15, 2004       |

 

----
No. 09-7699.

#### Bruce W. Hoffman, Petitioner v. Frances J. Hoffman.

559 U.S. 1117, 130 S. Ct. 2429,

176 L. Ed. 2d 942,

2010 U.S. LEXIS 3849.

May 3, 2010.

Petition for rehearing denied.

Former decision, 559 U.S. 1009, 130 S. Ct. 1882, 176 L. Ed. 2d 370, 2010 U.S. LEXIS 2688.
No. 09-767.

#### SKF USA, Inc., Petitioner v. Customs and Border Protection, et al.

560 U.S. 903, 130 S. Ct. 3273,

176 L. Ed. 2d 1182,

2010 U.S. LEXIS 3940.

May 17, 2010.

Petition for writ of cer-tiorari to the United States Court of Appeals for the Federal Circuit denied.

Same case below, 556 F.3d 1337.
No. 09-9680.

#### Furnell Severin, Petitioner v. Jefferson Parish, Louisiana, et al.

560 U.S. 911,130 S. Ct. 3291,

176 L. Ed. 2d 1196,

2010 U.S. LEXIS 3906.

May 17, 2010.

Petition for writ of cer-tiorari to the United States Court of Appeals for the Fifth Circuit denied.

Same case below, 357 Fed. Appx. 601.
No. 09-1190.

#### Brian Wallace, Administrator of the Estate of Norman E. Wallace, Petitioner v. Case Western Reserve University.

560 U.S. 906, 130 S. Ct. 3296,

176 L. Ed. 2d 1187,

2010 U.S. LEXIS 4000.

May 17, 2010.

Petition for writ of cer-tiorari to the Court of Appeals of Ohio, Cuyahoga County, denied.
### IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 16

- 50535 Summary Calendar

Cons. w/16

- 50536

UNITED STATES OF AMERICA , Plaintiff

- Appellee

v.
JASON C. MCCLURE , Defendant

- Appellant

Appeal s from the United States District Court for the Western District of Texas USDC No. 1:12

- CR

- 217

- 1 USDC No. 1:12

- CR

- 443

- 1

Before DAVIS, CLEMENT, and COSTA, Circuit Judges. PER CURIAM : * Jason C. McClure appeals his below guidelines sentence for conspir ing to possess with intent to distribute methylone, in violation of 21 U.S.C. §§ 841(a)(1) & (b)(1)(C), 846

. Because m ethylone is not specifically referenced in U.S.S.G. § 2D1.1(c) , in calculating the g uidelines range , the district court

* Pursuant to 5 TH C IR

. R. 47.5 , the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED July 27, 2017 Lyle W. Cayce Clerk Case: 16-50535 Document: 00514090995 Page: 1 Date Filed: 07/27/2017No. 16

- 50535 c/w No. 16

- 50536

2 determined that MDMA was the most closely related controlled substance and therefore applied MDMA ’s 500:1 drug equivalency ratio

. On appeal, McClure

c ontends that the district court did not recognize it s authority to reject the
500:1 ratio and vary below the calculated guidelines range on that basis

. Although McClure objected to the court’s use of the 500:1 ratio, he did not object to the district court’s explanation for denying his objection or
otherw ise suggest that the court had failed to recognize its discretion to grant a variance on that specific basis . Therefore, we review the forfeit ed objection under the plain error standard. See Puckett v. United States , 556 U.S. 129, 135 (2009). To satisfy that standard, McClure must show a n error that is “ clear or
obvious ” and that “ affects his substantial rights. ” See id. (internal quotation omitted). If he makes such a showing, this court has the discretion to correct the error but only if it seriously affects the fairness, integrity, or public reputation of judicial proceedings. See id

. Contrary to McClure’s interpretation of the court’s comments at sentencing, the record does not re flect that the district court misunderstood its authority to vary b elow the guidelines range if it disagreed with the 500:1 drug ratio. Instead, it shows that the court found the argument for applying a lower ratio to be “weak;” the court made an individualized determination of the sentencing factors and varied below the guidelines range for other reasons

. McClure has therefore failed to show that the court committed any clear or
obvious error. AFFIRMED. Case: 16-50535 Document: 00514090995 Page: 2 Date Filed: 07/27/2017
**Exhibit 32.2**

 

**CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Quarterly Report of Eon Labs, Inc. (the“Company”) on Form 10-Q for the period ended March 31, 2004 as filed withthe Securities and Exchange Commission on the date hereof (the “Report”), I,William F. Holt, Chief Financial Officer of the Company, certify, pursuant to18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-OxleyAct of 2002, that:

 

(1)                                  TheReport fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and

 

(2)                                  Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 
|   |  /s/ William F. Holt |   |
|--------|---------------------------|--------|
|   | William F. Holt           |
|   | Chief Financial Officer   |

 

May 7, 2004

 

1

----
Exhibit 35.14  LOGO 2018 Annual Statement of Servicer Compliance (Item 1123) Pooling and Servicing Agreement (the Pooling and Servicing Agreement) dated as of September 1, 2017 by and among Wells Fargo Commercial
Mortgage Securities, Inc., as Depositor, Wells Fargo Bank, National Association as General Master Servicer, Rialto Capital Advisors, LLC as General Special Servicer, National Cooperative Bank, N.A. as NCB Master Servicer and NCB Special Servicer,
Pentalpha Surveillance LLC as Operating Advisor and as Asset Representations Reviewer, Wells Fargo Bank, National Association as Certificate Administrator and Wilmington Trust, National Association as Trustee relating to the BANK 2017-BNK7,
Commercial Mortgage Pass-Through Certificates, Series 2017-BNK7 (BANK 2017-BNK7) The undersigned, a duly authorized officer of Rialto Capital
Advisors, LLC, as special servicer (the Special Servicer) herein certifies to the following:  1.
All servicing activities and performance of such servicing activities under the Pooling and Servicing Agreement
are performed on behalf of the Special Servicer.  2.
A review of the servicing activities and performance by the Special Servicer for the period of January 1,
2018 to December 31, 2018 (the Reporting Period) in accordance with the Pooling and Servicing Agreement has been conducted under my supervision.  3.
To the best of my knowledge, based on such review, the Special Servicer has fulfilled all of its obligations
under the terms of the Pooling and Servicing Agreement, in all material respects for the Reporting Period and if there has been a failure to fulfill any such obligations in any material respect, each failure and the nature and status thereof has
been specifically identified herein.  Certified by:

/s/ Adam Singer



Date: March 1, 2019Adam Singer, Managing Director
[Federal Register Volume 74, Number 42 (Thursday, March 5, 2009)]
[Notices]
[Page 9608]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-4709]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ID-5968-000]


Dawes, Peter E.; Notice of Filing

February 25, 2009.
    Take notice that on February 5, 2009, Peter E. Dawes submitted for 
filing, an application for authority to hold interlocking positions, 
pursuant to section 305(b) of the Federal Power Act, 16 U.S.C. 825d (b) 
(2008), and Part 45 of Title 18 of the Code of Federal Regulations, 18 
CFR part 45 (2008).
    Any person desiring to intervene or to protest this filing must 
file in accordance with Rules 211 and 214 of the Commission's Rules of 
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be 
considered by the Commission in determining the appropriate action to 
be taken, but will not serve to make protestants parties to the 
proceeding. Any person wishing to become a party must file a notice of 
intervention or motion to intervene, as appropriate. Such notices, 
motions, or protests must be filed on or before the comment date. On or 
before the comment date, it is not necessary to serve motions to 
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov. Persons unable to file electronically should submit an 
original and 14 copies of the protest or intervention to the Federal 
Energy Regulatory Commission, 888 First Street, NE., Washington, DC 
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the 
``eLibrary'' link and is available for review in the Commission's 
Public Reference Room in Washington, DC. There is an ``eSubscription'' 
link on the Web site that enables subscribers to receive e-mail 
notification when a document is added to a subscribed docket(s). For 
assistance with any FERC Online service, please e-mail 
<a href="/cdn-cgi/l/email-protection#d89e9d8a9b97b6b4b1b6bd8bada8a8b7aaac98bebdaabbf6bfb7ae"><span class="__cf_email__" data-cfemail="266063746569484a4f484375535656495452664043544508414950">[email protected]</span></a>, or call (866) 208-3676 (toll free). For 
TTY, call (202) 502-8659.
    Comment Date: 5 p.m. Eastern Time on March 12, 2009.

Kimberly D. Bose,
Secretary.
 [FR Doc. E9-4709 Filed 3-4-09; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
No. 09-8090.

#### James T. Kincannon, Petitioner v. United States.

559 U.S. 1094, 130 S. Ct. 2372,

176 L. Ed. 2d 770,

2010 U.S. LEXIS 3634.

April 26, 2010.

Petition for writ of cer-tiorari to the United States Court of Appeals for the Seventh Circuit denied.

Same case below, 567 F.3d 893.
I 

109TH CONGRESS 

2D SESSION H. R. 4721 

To require the Secretary of Health and Human Services to provide Federal 

Medicaid funding for State costs associated with ensuring access to 

prescription drug benefits to part D eligible individuals. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 8, 2006 

Mr. EMANUEL (for himself and Ms. DELAURO) introduced the following bill; 

which was referred to the Committee on Energy and Commerce 

A BILL 

To require the Secretary of Health and Human Services 

to provide Federal Medicaid funding for State costs associated with ensuring access to prescription drug benefits 

to part D eligible individuals. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. FEDERAL MEDICAID FUNDING FOR STATE 

4 COSTS INCURRED TO ENSURE PRESCRIPTION 

5 DRUG ACCESS. 

6 (a) REIMBURSEMENT OF COSTS.—Notwithstanding 

7 section 1935(d)(1) of the Social Security Act (42 U.S.C. 

8 1396u-5(d)(1)), the Secretary of Health and Human Serv-
2 

•HR 4721 IH 

1 ices shall make available to a State under section 1903(a) 

2 of such Act (42 U.S.C. 1396b(a)) Federal financial par3 ticipation with respect to costs, including administrative 

4 costs, incurred by such State (as reported by the State) 

5 on or after January 1, 2006— 

6 (1) for medical assistance for covered part D 

7 drugs for full-benefit dual eligible individuals who 

8 are enrolled under a prescription drug plan under 

9 part D of title XVIII of such Act (or an MA–PD 

10 plan under part C of such title) but who were not 

11 reasonably able to access on a timely basis prescrip12 tion drug benefits to which they were entitled under 

13 such part; and 

14 (2) which the State reasonably expected would 

15 have been covered under such part. 

16 (b) RECOVERY OF REIMBURSEMENT AMOUNTS FROM

17 PLANS.—The Secretary of Health and Human Services 

18 shall provide for the recovery of the amount of Federal 

19 financial participation made available to States under sub20 section (a) from prescription drug plans under part D of 

21 title XVIII of the Social Security Act (and MA–PD plans 

22 under part C of such title) if the Secretary determines 

23 that such plans should have incurred such costs. Amounts 

24 recovered pursuant to the preceeding sentence shall be 

25 treated in the same manner as the recovery of third party 
3 

•HR 4721 IH 

1 liability under section 1902(a)(25) of the Social Security 

2 Act (42 U.S.C. 1396a(a)(25)). 

3 (c) DEFINITIONS.—For purposes of this section: 

4 (1) COVERED PART D DRUG.—The term ‘‘cov5 ered part D drug’’ has the meaning given such term 

6 in section 1860D–2(e) of the Social Security Act (42 

7 U.S.C. 1395w–102(e)). 

8 (2) FULL-BENEFIT DUAL ELIGIBLE INDI9 VIDUAL.—The term ‘‘full-benefit dual eligible indi10 vidual’’ has the meaning given such term in section 

11 1935(c)(6) of the Social Security Act (42 U.S.C. 

12 1396u–5(c)(6)). 

13 (3) STATE.—The term ‘‘State’’ means each of 

14 the 50 States and the District of Columbia. 

Æ
Date: 16 August 2023 *******************

NSN: 8920017091613 (MLB) MONOGRAPH 3D3

 *******************

Item: Brownie, Type I, Flavor 1

Document: PCR-M-018, Mini Loaves and Muffins, Packaged in a Polymeric Tray, Shelf Stable

Approximate Caloric Value Per Serving: 243 Component Classification: Primary

Estimated Shelf Life: 36 months at 80°F

Item Characteristics

Appearance:

Fully baked, intact, individual, rectangular brownie loaf, medium to dark brown 

exterior and interior crumb color. Dimensions not less than 3 inches long by 1-2/5 

inches wide. The interior crumb may have air pockets distributed throughout. Height 

measured at highest point shall be not less than 1-1/4 inch.

Odor: Sweet, mild chocolate. 

Flavor: Sweet, mild chocolate.

Texture: Dense, moist, and firm.

Possible Deteriorative Changes 

Appearance: Darkening color of interior and exterior crumb..

Odor: Oxidized, low/no chocolate.

Flavor: Oxidized, low/no chocolate.

Texture: Gummy, excessively moist, excessively dense.

Unique Examination/Test Procedures

Special Notes
```
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cirracor, Inc. a Nevada corporation
(the "Company") on Form 10-QSB for the period ending December 31, 2005, as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
Reed Fisher, Chief Executive Officer and Chief Financial Officer of the Company,
certifies to the best of his knowledge, pursuant to 18 U.S.C. ss. 1350, as
adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company. A
signed original of this written statement required by Section 906 has been
provided to Cirracor, Inc., and will be retained by Cirracor, Inc. and furnished
to the Securities and Exchange Commission or its staff upon request.

/s/ Reed Fisher
--------------------------
Reed Fisher
Chief Financial Officer
August 4, 2006
```
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health 

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. 

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. 

*Name of Committee:*                         National Library of Medicine Special Emphasis Panel, Loan Repayment Program (L30-L40) Review.                     

Date: April 21, 2009.

Time: 12 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Library of Medicine, 6705 Rockledge Drive, Suite 301, Bethesda, MD 20892 (Telephone Conference Call).

                        Contact Person: Zoe E. Huang, M.D., Scientific Review Officer, Extramural                               ( print page 10260)                            Programs, National Library of Medicine, NIH, 6705 Rockledge Drive, Suite 301, Bethesda, MD 20892-7968, (301) 594-4937,                         *huangz@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: March 3, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory Committee Policy.

 [FR Doc. E9-4975 Filed 3-9-09; 8:45 am] 

BILLING CODE 4140-01-P
Exhibit 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Donald Neal, President, Chief Executive Officer, Secretary, and
Treasurer of American  Goldfields  Inc. (the  "Company"),  certifies,  under the
standards  set forth and solely for the purposes of 18 U.S.C.  1350,  as adopted
pursuant  to  Section  906  of the  Sarbanes-Oxley  Act of  2002,  that,  to his
knowledge,  the  Quarterly  Report on Form 10-QSB of the Company for the quarter
ended October 31, 2006 fully complies with the  requirements of Section 13(a) or
15(d) of the Securities  Exchange Act of 1934 and information  contained in that
Form 10-QSB fairly presents,  in all material respects,  the financial condition
and results of operations of the Company.


Date: December 7, 2006



/s/ Donald Neal
---------------------
Donald Neal
President, Chief Executive Officer,
Secretary, and Treasurer
(Principal Executive Officer,
Principal Financial Officer, and Principal Accounting Officer)


This  certification  accompanies  the  Report  pursuant  to  Section  906 of the
Sarbanes-Oxley  Act of 2002 and shall not,  except to the extent required by the
Sarbanes-Oxley  Act of 2002,  be deemed  filed by the  Company  for  purposes of
Section 18 of the Securities Exchange Act of 1934, as amended.

A signed  original  of this  written  statement  required  by Section 906 of the
Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained
by the Company and furnished to the  Securities  and Exchange  Commission or its
staff upon request.




                                       13
<PAGE>
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5080 Introduced in House (IH)]

109th CONGRESS
  2d Session
                                H. R. 5080

 To provide for the expansion of human clinical trials qualifying for 
                        the orphan drug credit.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 4, 2006

Mr. Brady of Texas introduced the following bill; which was referred to 
                    the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
 To provide for the expansion of human clinical trials qualifying for 
                        the orphan drug credit.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Orphan Drug Tax Credit Act of 
2006''.

SEC. 2. EXPANSION OF HUMAN CLINICAL TRIALS QUALIFYING FOR ORPHAN DRUG 
              CREDIT.

    (a) In General.--Subclause (I) of section 45C(b)(2)(A)(ii) of the 
Internal Revenue Code of 1986 is amended to read as follows:
                                    ``(I) after the date that the 
                                application is filed for designation 
                                under such section 526, and''.
    (b) Conforming Amendment.--Clause (i) of section 45C(b)(2)(A) of 
such Code is amended by inserting ``which is'' before ``being'' and by 
inserting before the comma at the end ``and which is designated under 
section 526 of such Act''.
    (c) Effective Date.--The amendments made by this Act shall apply to 
amounts paid or incurred after the date of the enactment of this Act.
                                 <all>
```
Court of Appeals 

First District of Texas 

BILL OF COSTS

No. 01-16-00276-CV

Robert Davenport and Jayne Edison 

v.

Dr. Samuel Maxwell Adu-Lartey and Athletic Orthopedics and Knee Center, P.A. d/b/a AOK 

Orthopedics

NO. 2014-71784 IN THE 189TH DISTRICT COURT OF HARRIS COUNTY

TYPE OF FEE CHARGES PAID/DUE STATUS PAID BY

MT FEE

SUPP CLK RECORD

CLK RECORD

MT FEE

FILING

STATEWIDE EFILING

$10.00

$33.00

$582.00

$10.00

$175.00

$30.00

12/19/2016

05/26/2016

05/06/2016

04/07/2016

04/05/2016

04/05/2016

E-PAID

PAID

PAID

E-PAID

E-PAID

E-PAID

ANT

ANT

ANT

ANT

ANT

ANT

The costs incurred on appeal to the First Court of Appeals Houston, Texas are 

$840.00.

Court costs in this case have been taxed in this Court’s judgment

I, Christopher A. Prine, Clerk of the Court of Appeals for the First District of Texas, do hereby 

certify that this is a true statement of the costs of appeal in this case.
IN TESTIMONY WHEREOF, witness my 

hand and the seal of the Court of Appeals for the 

First District of Texas, this 25th day of May, 

2018.